1 / 13

Global Hepatitis Drugs Market Analysis| Coherent Market Insights

The global hepatitis drugs market size was leading by value at US$ 21,148.3 million in 2019.

shrutiCMI
Download Presentation

Global Hepatitis Drugs Market Analysis| Coherent Market Insights

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Coherent Market Insights Market Research and Business Consulting Services https://www.coherentmarketinsights.com/ COVID-19 Impact Tracker

  2. HEPATITIS DRUGS MARKET ANALYSIS Global Hepatitis Drugs Market,ByDrug Class (Interferon Alphas, HIV NRTIs, Nucleotide Polymerase/NS5A Inhibitor Combinations, Hepatitis C Protease/NS5A Inhibitor Combinations, NS5A Inhibitors, Nucleotide Polymerase Inhibitors, Nucleoside Analogue Antivirals, and Thrombopoiesis Stimulating Agents), By Disease Type (Hepatitis B, Hepatitis C, and Others), By Route of Administration (Oral and injection), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019-2027

  3. The global hepatitis drugs market size was valued at US$ 21,148.3 million in 2019, and is expected to witness a CAGR of 3.2% over the forecast period (2019 – 2027). Growth Drivers • Increasing approvals for hepatitis drugs from regulatory authorities is expected to drive the global hepatitis drugs market growth during the forecast period. For instance, in 2016, the U.S. FDA approved the Elbasvir drug for the treatment of hepatitis C, Elbasvir is a highly potent and selective NS5A inhibitor of the hepatitis C virus NS5A replication complex. • Launch of new drugs for hepatitis treatment is expected to drive growth of the hepatitis drugs market during the forecast period. For instance, in 2018, NatcoPharma has launched a fixed dose combination of Sofosbuvir-Daclatasvir tablets for the treatment of Hepatitis C under the brand name Hepcinat Plus, in India.

  4. Global Hepatitis Drugs Market Share (%) Analysis,ByDrug Class,2019

  5. Market Restraints The high capital requirement for manufacturing hepatitis drugs is expected to hinder growth of the hepatitis drugs market over the forecast period. Hepatitis drugs are costly as the manufacturing process requires expensive raw materials such as active pharmaceutical ingredients (APIs) and drug intermediates. The production, isolation, and usage of raw materials for pharmaceutical and biopharmaceutical drug production, is a complex process and requires a skilled workforce, which adds to the overall cost of the pharmaceuticals.

  6. Regional Insights • On the basis of region, the global hepatitis drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global hepatitis drugs market over the forecast period, owing to increasing government initiative for the prevention of HBV infection. For instance, in 2017, the U.S. Department of Health And Human Service started the National Viral Hepatitis Action Plan 2017-2020 (Action Plan) to fight against viral hepatitis in the US. The plan outlines strategies to achieve four major goals between 2017 and 2020, such as preventing new viral hepatitis infections, reducing deaths and improving the health of people with viral hepatitis.

  7. Asia Pacific is expected to witness a rapid growth in the global hepatitis drugs market over the forecast period owing to rising demand for generic drugs in this region. For instance in 2015, Gilead licensed its hepatitis C drug Sovaldi to seven generic drug manufacturers companies in India to make and sell a low-cost version of the medicine in 91 emerging economies.

  8. Global Hepatitis Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2016-2027

  9. Competitive Section Key players operating in the global hepatitis drugs market include Merck & Co. Inc., Gilead Sciences Inc., AbbVie Inc., Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., LAURUS Labs, ZydusCadila, Hetero Healthcare Limited, GlaxoSmithKline PLC., and Cipla Inc.

  10. Request Sample Report • Request Customization • Download PDF Brochure • Talk to Analyst Reference: https://www.coherentmarketinsights.com/market-insight/hepatitis-drugs-market-2977

  11. About Us Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. What we provide: • Customized Market Research Services • Industry Analysis Services • Business Consulting Services • Market Intelligence Services • Long term Engagement Model • Country Specific Analysis

  12. Contact Us Mr. Shah Coherent Market Insights Pvt.Ltd. Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Phone: +1-206-701-6702 Email: sales@coherentmarketinsights.com

  13. Thank You! Kindly follow CMI Social Media Profiles for the latest company updates Facebook Linkedin Twitter https://www.coherentmarketinsights.com/

More Related